IAPIG REC'TPTO 18 SEP 2006 10/593432

INFORMATION DISCLOSURE **STATEMENT** Patent Application Docket No. ARS-131

September 18, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Kinsey Maundrell

Filed

September 18, 2006

For

Anti-Lipid Rafts Antibodies

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 CFR §§1.97 AND 1.98</u>

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully assertsthat the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

J:\ARS\131\PTO-Misc\IDS.doc/DNB/fes

IAP16 Rec'd PCT/PTO 18 SEP 2006. 90/593432

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number		
INFORMATION DISCLOSURE				Filing Date September 18, 200	September 18, 2006	
SIAIE	STATEMENT BY APPLICANT			First Named Inventor	Kinsey Maundrell	
(use as many sheets as necessary)				Art Unit		
				Examiner Name		
Sheet	1	of	_2	Attorney Docket Number	ARS-131	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-				
	U2	US-				
	U3	US-				
	U4	US-				
	U5	US-				
	U6	US-				
	U7	US-				
	U8	US-				
	U9	US-				

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁴
	F1	WO 02/048302	06/12/2003	Protein Design Labs Inc.	All	
	F2					
	F3					
,	F4					
	F5		~~~~			
	F6					
	F7					

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP16 Rec'd PCT/PTO 18 SEP 2006

10/593432

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** INFORMATION DISCLOSURE **Filing Date** September 18, 2006 STATEMENT BY APPLICANT First Named Inventor Kinsey Maundrell **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet of 2 **Attorney Docket Number ARS-131** 2

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	R1	FANTINI, J. et al. "Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases" Expert Reviews in Molecular Medicine, December 20, 2002, pp. 1-122, Vol. 2002.			
·	R2	BUTLER, D.A. et al. "Scrapie-Infected Murine Neuroblastoma Cells Produce Protease-Resistant Prion Proteins" Journal of Virology, May 1998, pp. 1558-1564, Vol. 62, No. 5.			
	R3	SABORIO, G.P. et al. "Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding" <i>Nature</i> , June 14, 2001, pp. 810-813, Vol. 411, No. 6839.			
	R4				
	R5				
	R6				
•	R7				
	R8				
	R9				
	R10				
	R11				
-	R12				

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2